Navigation Links
Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Date:6/19/2008

AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008

NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City Fire Department Emergency Medical Technician whose diabetes was allegedly caused by AstraZeneca's drug Seroquel. The plaintiff, EMT Ernest Armstead, was one of the many brave responders on the morning of September 11, 2001. He was severely injured when the World Trade Center's North Tower collapsed as he was helping victims at the foot of the buildings.

Suffering from Post-Traumatic Stress Disorder after recovery from his 9/11 physical injuries, Mr. Armstead was prescribed Seroquel, which Weitz & Luxenberg claims did not carry a warning that the powerful drug can cause diabetes. He thereafter developed the debilitating, life-long disease known as Type 2 diabetes. Mr. Armstead joins thousands of others across the country who has filed actions claiming that Seroquel caused them to develop diabetes and that AstraZeneca hid its knowledge of this risk from the FDA, doctors and patients.

In a letter dated November 16, 2006, the Department of Health and Human Services of the Food and Drug Administration cited violations of the Federal Food, Drug, and Cosmetic Act in connection with AstraZeneca's use of promotional material deemed by the FDA to be "false or misleading because it minimizes the risk of hyperglycemia and diabetes mellitus" and which "raises significant public health and safety concerns through its minimization of the risks associated with Seroquel."

A deposition of AstraZeneca's Chief Executive Officer, David Brennan, about his company's alleged undisclosed knowledge regarding the dangerous side effect of diabetes, is being taken this Friday, June 20th in London, England at the law offices of Baker Botts, a U.S. firm defending the company. Lawyers from three of the lead plaintiffs' counsel in the litigation (Blizzard, McCarthy & Nabers; Weitz & Luxenberg; and Bailey, Perrin, Bailey) will be conducting the deposition.

About Weitz & Luxenberg P.C.: Weitz & Luxenberg, founded in 1986, is one of the leading plaintiffs' litigation law firms in America. The firm has played leading roles in national and local litigations involving asbestos/mesothelioma, DES, silicone breast implants, defective medicines and medical devices, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE among other toxins. The firm recently secured a landmark MTBE settlement against some of the country's biggest oil companies, which have agreed to pay $423 million in a suit involving the contamination of 153 public water systems nationally.


'/>"/>
SOURCE Weitz & Luxenberg, PC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
2. Jazz Pharmaceuticals Files Form S-3 Registration Statements
3. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. Immunosyn Corporation Files 10-Q
6. Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
7. Benda Pharmaceutical Files Amendment To Form S-1
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Vion Pharmaceuticals Files Plan With Nasdaq
10. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network ... and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... 2016  IsoRay, Inc. (NYSE MKT: ISR), a medical ... radioisotope applications for the treatment of prostate, brain, lung, ... financial results for the second quarter and six months ... --> --> Revenue ... 2016, which ended December 31, 2015, a 12% increase ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):